drugset / Trial / NCT01855828
Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
The main goal of this clinical trial is to test if adding pertuzumab (Perjeta), improves the anticancer activity of the combination chemotherapy regimen of trastuzumab (Herceptin) concomitant with paclitaxel, 5-fluorouracil, epirubicin, and cyclophosphamide (T-FEC). The study will also test the safety of this therapy.
Timeline
- Start
- 2013-09
- Primary completion
- 2018-08
- Completion
- 2018-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pertuzumab | Monoclonal antibody | 420 mg | — |
| Background | Cyclophosphamide | Other / unclassified | 500 mg/m2 | — |
| Background | Epirubicin | Small molecule | 75 mg/m2 | — |
| Background | Paclitaxel | Small molecule | 80 mg/m2 | — |
| Background | Trastuzumab | Monoclonal antibody | 2 mg/kg | — |
| Background | fluorouracil | Small molecule | 500 mg/m2 | — |